Study to assess the safety and efficacy of denosumab vs. placebo in children with glucocorticoid-induced osteoporosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003083-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 years of age with glucocorticoid (GC)-induced osteoporosis (GiOP).


Critère d'inclusion

  • Glucocorticoid-induced osteoporosis

Liens